Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment (Q38044744)

27 August 2017

title

Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment (English)

1 reference

27 August 2017

main subject

phase II clinical trial

0 references

tuberculosis

0 references

bedaquiline

1 reference

ChEBI release 2020-05-28

1 reference

Jean Engohang-Ndong

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

19 September 2012

1 reference

Expert Opinion on Investigational Drugs

27 August 2017

published in

1 reference

27 August 2017

volume

21

1 reference

27 August 2017

issue

12

1 reference

27 August 2017

page(s)

1789-1800

1 reference

Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Nervous system effects of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

The role of fluoroquinolones in tuberculosis today

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Fluoroquinolones and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Mycolic acid synthesis: a target for ethionamide in mycobacteria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

The mechanism of action of PA-824: Novel insights from transcriptional profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Phase II dose-ranging trial of the early bactericidal activity of PA-824

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Delamanid for multidrug-resistant pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Structural mechanisms of QacR induction and multidrug recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Synthetic EthR inhibitors boost antituberculous activity of ethionamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Chemical modification of capuramycins to enhance antibacterial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

In vitro antimycobacterial activities of capuramycin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

PARA-AMINOSALICYLIC ACID IN THE TREATMENT OF TUBERCULOSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.724397

Studies on novel bacterial translocase I inhibitors, A-500359s. I. Taxonomy, fermentation, isolation, physico-chemical properties and structure elucidation of A-500359 A, C, D and G.

21 January 2018

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.56.243

10.1517/13543784.2012.724397

12 April 2024

Identifiers

DOI

1 reference

27 August 2017

1 reference